Xenetic Biosciences XBIOW Stock
Xenetic Biosciences Price Chart
Xenetic Biosciences XBIOW Financial and Trading Overview
| Xenetic Biosciences stock price | 17.54 USD |
| Previous Close | 22.94 USD |
| Open | 16.7 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 17.54 - 17.54 USD |
| 52 Week Range | 1.02 - 20.5 USD |
| Volume | 2 USD |
| Avg. Volume | 635 USD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.3 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
XBIOW Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.1148999 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Xenetic Biosciences Stock Price History
| Beta (5Y Monthly) | 2.3 |
| 52-Week Change | 69.63% |
| S&P500 52-Week Change | 27.18% |
| 52 Week High | 20.5 USD |
| 52 Week Low | 1.02 USD |
| 50-Day Moving Average | 12.44 USD |
| 200-Day Moving Average | 9.05 USD |
XBIOW Share Statistics
| Avg. Volume (3 month) | 635 USD |
| Avg. Daily Volume (10-Days) | 1.02K USD |
| Shares Outstanding | N/A |
| Float | 1.18M |
| Short Ratio | N/A |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | N/A |
| Most Recent Quarter (mrq) | N/A |
| Next Fiscal Year End | N/A |
Profitability
| Profit Margin | -182.95% |
| Operating Margin (ttm) | -248.31% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.33% |
| Return on Equity (ttm) | -41.53% |
Income Statement
| Revenue (ttm) | 2.44M USD |
| Revenue Per Share (ttm) | 1.59 USD |
| Quarterly Revenue Growth (yoy) | -15.69% |
| Gross Profit (ttm) | 2.44M USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -4473137 USD |
| Diluted EPS (ttm) | N/A |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 7.82M USD |
| Total Cash Per Share (mrq) | 5.08 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 11.69 |
| Book Value Per Share (mrq) | 5.631 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4171126 USD |
| Levered Free Cash Flow (ttm) | -2567164 USD |
Profile of Xenetic Biosciences
| Country | United States |
| State | MA |
| City | Framingham |
| Address | 945 Concord Street |
| ZIP | 01701 |
| Phone | 781 778 7720 |
| Website | https://www.xeneticbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Q&A For Xenetic Biosciences Stock
What is a current XBIOW stock price?
Xenetic Biosciences XBIOW stock price today per share is 17.54 USD.
How to purchase Xenetic Biosciences stock?
You can buy XBIOW shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xenetic Biosciences?
The stock symbol or ticker of Xenetic Biosciences is XBIOW.
Which industry does the Xenetic Biosciences company belong to?
The Xenetic Biosciences industry is Biotechnology.
How many shares does Xenetic Biosciences have in circulation?
The max supply of Xenetic Biosciences shares is 0.
What is Xenetic Biosciences Price to Earnings Ratio (PE Ratio)?
Xenetic Biosciences PE Ratio is now.
What was Xenetic Biosciences earnings per share over the trailing 12 months (TTM)?
Xenetic Biosciences EPS is 0 USD over the trailing 12 months.
Which sector does the Xenetic Biosciences company belong to?
The Xenetic Biosciences sector is Healthcare.